• SPX
  • $5,973.10
  • 0.74 %
  • $44.06
  • DJI
  • $43,729.34
  • -0 %
  • -$0.59
  • N225
  • $39,500.15
  • 0.3 %
  • $118.96
  • FTSE
  • $8,140.74
  • -0.32 %
  • -$25.94
  • IXIC
  • $19,269.46
  • 1.51 %
  • $285.99
Glaukos Corporation (GKOS) Stock Price, News & Analysis

Glaukos Corporation (GKOS) Stock Price, News & Analysis

Currency in USD Disclaimer

$139.31

-$1.34

(-0.95%)

Day's range
$136.08
Day's range
$142.77
50-day range
$119.54
Day's range
$143.24
  • Country: US
  • ISIN: US3773221029
52 wk range
$59.22
Day's range
$142.77
  • CEO: Mr. Thomas William Burns
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 17.10
  • Piotroski Score 4.00
  • Grade Overweight
  • Symbol (GKOS)
  • Company Glaukos Corporation
  • Price $139.31
  • Changes Percentage (-0.95%)
  • Change -$1.34
  • Day Low $136.08
  • Day High $142.77
  • Year High $142.77

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/19/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $140.00
  • High Stock Price Target $155.00
  • Low Stock Price Target $42.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.88
  • Trailing P/E Ratio -39.55
  • Forward P/E Ratio -39.55
  • P/E Growth -39.55
  • Net Income $-134,661,000

Income Statement

Quarterly

Annual

Latest News of GKOS

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

  • Here's Why Glaukos (GKOS) Appreciated in Q2

    Brown Capital Management's Small Company Fund had a -6.57% return in Q2 2024, underperforming the Russell 2000 Growth index. Glaukos Corporation (NYSE:GKOS) was highlighted as a top pick, with a one-m...

    By Yahoo! Finance | 1 month ago
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.